# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001493152-24-039556
Filing Date
2024-10-04
Accepted
2024-10-04 17:02:48
Documents
18
Period of Report
2024-09-30
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | form8-k.htm iXBRL | 8-K | 45887
2 |  | ex16-1.htm | EX-16.1 | 6192
3 |  | ex16-1_001.jpg | GRAPHIC | 505853
4 |  | ex16-1_002.jpg | GRAPHIC | 102871
5 |  | ex16-1_003.jpg | GRAPHIC | 949714
| Complete submission text file | 0001493152-24-039556.txt |  | 2374926

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL SCHEMA FILE | tnfa-20240930.xsd | EX-101.SCH | 3018
7 | XBRL LABEL FILE | tnfa-20240930_lab.xml | EX-101.LAB | 34240
8 | XBRL PRESENTATION FILE | tnfa-20240930_pre.xml | EX-101.PRE | 24167
21 | EXTRACTED XBRL INSTANCE DOCUMENT | form8-k_htm.xml | XML | 3697

Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 241355548
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)